We recently reported that interleukin-1␤ (IL-1␤
been proposed that the inflammatory response associated with these pathophysiological states results from the release of proinflammatory cytokines by monocyte/macrophages, which leads to the transient suppression of cardiac contractility (3) . Similar reversible negative inotropic effects are also observed during the reperfusion phase following myocardial infarction or cardiopulmonary bypass, commonly referred to as "stunned myocardium" (4 -6) . Taken together, such observations have led to the suggestion that cytokines could be, at least in part, responsible for stunning (7) .
Recent studies have suggested that cytokine-induced myocardial depression is due to alterations in intracellular calcium regulation, with both abnormal channel activity and myofilament calcium sensitivity being reported (8 -10) . Since the Ca 2ϩ -dependent ATPase of the myocardial sarcoplasmic reticulum (SERCA 2a) plays a major role in the regulation of myocyte calcium homeostasis, it too could play an important role in the myocyte response to cytokines (11) . Since increased catecholamine levels are a major cause of both increased contractility and intracellular Ca 2ϩ , it is noteworthy that cytokines are able to modulate adrenergic stimulation in the heart. For instance, after treatment with IL-1␤, myocytes exposed to catecholamines show an inhibition of the ␤-adrenergic mediated increase in cyclic AMP content and an uncoupling of adenylate cyclase from the ␤-receptor (12, 13) . In addition, observations in systemic blood vessels demonstrate that IL-1␤ can induce relaxation after precontraction with the ␣ 1 -adrenergic agonist phenylephrine (14 -16) , and IL 1 -1␤-induced relaxation of precontracted rat aortic rings is associated with a decrease in contractile protein isoform expression (17) .
We demonstrated recently that IL-1␤ induces cardiac myocyte hypertrophy while inhibiting cardiac fibroblast proliferation. This myocyte hypertrophy is associated with an increase in total protein content and the re-initiation of DNA synthesis. Despite the increase in protein, however, no enhanced expression of contractile protein mRNA in myocytes could be detected after 48 h of IL-1␤ treatment (18) . This is in marked contrast to other forms of hypertrophy induced by catecholamines, vasoactive peptides, or other peptide growth factors, which are accompanied by characteristic changes in contractile protein isogene expression (19 -22) and suggests that IL-1␤ may induce an even more "primitive" developmental phenotype than these other agents.
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‡ To whom correspondence should be addressed norepinephrine results in the preferential up-regulation of skeletal ␣-actin, ␤-MHC, and atrial natriuretic factor gene expression (the "fetal/neonatal program"), while the cardiac ␣-actin and ␣-MHC isogenes, predominantly expressed in the adult heart, are not activated. This specific isogene switching is reflected by changes in both mRNA and protein levels and is the direct result of action at the transcriptional level (23, 24) . Using transient transfection of a series of promoter constructs for the skeletal ␣-actin and ␤-MHC genes, our co-workers have identified both potential second messenger signaling pathways and the minimal promoter elements required for ␣ 1 -adrenoreceptor-mediated induction of these two genes (25, 26) .
In view of the antagonistic effects of cytokines on adrenergic signaling in vivo and our observations on the failure of IL-1␤ to induce the fetal program of gene transcription, we hypothesized that IL-1␤ could act as a negative modulator of the myocyte proteins regulated by catecholamines. Accordingly, we co-treated neonatal cardiac myocytes with the ␣ 1 -agonist phenylephrine and IL-1␤ to examine a possible effect of IL-1␤ on myocyte gene expression.
Our results show that IL-1␤ acts as a negative regulator of ␣ 1 -adrenergic induced skeletal ␣-actin and ␤-MHC gene expression. This repression is a direct result of action at the transcriptional level and may involve the bifunctional transcription factor YY1. To our knowledge this is the first report on the active repression of an induced cardiomyocyte phenotype in culture. Furthermore, these findings may provide a mechanism for the reported negative inotropic effect of cytokines such as IL-1␤ on myocardial function in vivo and may provide new insight into the mechanism(s) responsible for the expression of the differentiated phenotype by cardiac myocytes.
EXPERIMENTAL PROCEDURES
Plasmids-The promoter constructs for rat ␤-MHC and mouse skeletal ␣-actin driving the chloramphenicol acetyltransferase (CAT) reporter gene were used as described previously (26, 27) . The rat Ϫ3500 SERCA 2a-CAT reporter plasmid and the rat SERCA 2a cDNA were kindly provided by W. Dillmann (28) . The chicken ␤-actin-CAT plasmid was obtained from J. Mar and C. Ordahl (29) and the c-fos-CAT construct from G. M. Cooper (30) . The chicken skeletal ␣-actin promoter (Ϫ394 to ϩ24) linked to the firefly luciferase gene with and without mutations in the YY1 binding sequence and the YY1-expression vector were kindly provided by M. Schneider and R. J. Schwartz (31, 32) , respectively. The SV40-SEAP (secreted alkaline phosphatase) reporter plasmid was obtained from Clontech (Palo Alto, CA).
The Ϫ113 skeletal ␣-actin mutant was generated by PCR using site-directed mutagenesis of the parent construct. The mutated 5Ј oligonucleotide, 5Ј-GAGCTCGGTACCCACTCTAGTGCCCGACACCCAAATATGGCgcGGGAAGGG-3Ј, and a 3Ј oligonucleotide complementary to the SP6 polymerase binding site were amplified, cut with KpnI and XmaI, and subcloned into Ϫ46-skAct-CAT generated from SP64-CAT (26), thus recreating a YY1 site in the Ϫ113 construct. The incorporation of the mutated sequence was confirmed by dideoxy sequencing on an automated sequencer (Biomolecular Research Core, University of California San Francisco).
Cell Culture and Transfection-Low density (150 -200 cells/mm 2 ) primary cultures of neonatal rat cardiac myocytes were established and maintained in 60-mm dishes as described previously (33) . Contaminating fibroblasts were Ͻ10% of total cell number. Twenty-four hours after plating, medium was changed to minimum Eagle's medium with Hanks' salts containing 5% calf serum and 30 mM HEPES, pH 7.5. Duplicate dishes were transfected using the CaPO 4 method (26) . Equimolar amounts of CAT-reporter plasmids (1.8 pmol, 5-8 g) or luciferasereporter constructs (7.5 g) were transfected together with variable amounts of salmon sperm DNA to adust total DNA to 25 g/dish. In co-expression experiments, 2 g of the YY1-EMSV expression vector were used. SV40-SEAP plasmid (0.04 pmol, 0.2 g) was included in all dishes to correct for transfection efficiency. After 2 h the CaPO 4 precipitate was removed from the cells, and the medium was changed to serum-free medium (minimum Eagle's medium) supplemented with porcine insulin (10 g/ml) (Lilly), bovine transferrin (10 g/ml) (HyClone, Logan, UT), bovine serum albumin (1 mg/ml) (Intergen number 3130-00, Armour Pharmaceutical, Kankakee, IL), and bromodeoxyuridine (0.1 mM) (Sigma). After overnight incubation, fresh serum-free medium was added, and the cells were treated with 1 ng/ml recombinant mouse IL-1␤ (Genzyme, Cambridge, MA) and/or 20 M L-phenylephrine HCl (Sigma) or their vehicles (100 M ascorbic acid for phenylephrine and 1 ϫ phosphate-buffered saline ϩ 1% bovine serum albumin for IL-1␤). After 48 h, 75 l of medium was taken to measure SEAP activity, and cells were harvested for CAT assay.
Preparations of cell extracts and CAT assays were performed as described previously (34) . Cells transfected with the c-fos promoter were harvested after 24 h, and CAT assays were performed using 20% of the cell extract. Luciferase assays for the chicken skeletal ␣-actin constructs were performed with 20% of cell extract. The amount of secreted alkaline phosphatase was detected in culture medium after 48 h using the Great EscAPe Detection Kit (Clontech, Palo Alto, CA) according to the manufacturer's protocol. SEAP activity was similar among groups with different reporter plasmids and was not affected by treatment with IL-1␤ or phenylephrine (data not shown). CAT, luciferase, and SEAP activities were assayed within the linear range and CAT or luciferase activities were normalized relative to the SEAP activity in the same dish. Co-transfected SV40-SEAP did not show any promoter competition with the CAT reporter plasmids used in this study. All transfection studies were performed with at least two independent plasmid preparations.
RNA Analysis-For Northern analysis, 100-mm dishes of low density neonatal rat cardiac myocytes were incubated in serum-free medium and treated with IL-1␤ and/or L-phenylephrine or their vehicles as described above. After 48 h, total cellular RNA was isolated by the guanidinium thiocyanate phenol-chloroform method (35) . Fifteen g of total RNA per lane was size-fractionated by formaldehyde-agarose gel electrophoresis, transferred to nylon membranes (Schleicher & Schuell), and immobilized by UV cross-linking (Stratalinker, Stratagene, La Jolla, CA).
Blots were hybridized with rat ␣-or ␤-MHC-specific oligonucleotides (Oncogene Science, San Diego, CA). Probes were end-labeled with [␥- 32 P]ATP to a specific activity of 4 -6 ϫ 10 7 cpm/g DNA using T 4 polynucleotide kinase (Life Technologies, Inc., Gaithersburg, MD). After hybridization for 20 h at 42°C, blots were washed in 6 ϫ SSC and 0.1% SDS for 30 min at 42°C and in 1 ϫ SSC and 1% SDS for 15 min at 42°C. Gene-specific riboprobes were used for c-fos, c-myc, and GAPDH mRNA expression. The antisense probes were labeled with ␣ 32 P-UTP to a specific activity of 4 -6 ϫ 10 7 cpm/g DNA using the Maxiscript T7/T3 Kit (Ambion, Austin, TX). After hybridization for 20 h at 65°C, blots were washed in 150 mM NaPO 4, 1% SDS for 30 min at 65°C. All blots were exposed to x-ray film (Eastman Kodak Co., Biomax-MR) at Ϫ70°C using an intensifying screen. Gene-specific signals were quantified by scanning densitometry (Scan Analysis, Biosoft) and normalized to GAPDH expression as described previously (36) .
Skeletal ␣-actin and SERCA 2a mRNA were detected using RNase protection (RPAII, Ambion). For these studies, 2.5 g of total RNA were hybridized overnight at 52°C with [␣-32 P]UTP-labeled antisense probes complementary to 195 bp of the last coding exon of the skeletal ␣-actin gene (18) , 331 bp of the SERCA gene (37) , and a 316-bp fragment of the rat GAPDH gene (Ambion). Following digestion with RNase A/T1 (1: 100), protected fragments were separated on a 6% denaturing polyacrylamide gel, subjected to autoradiography, and normalized to GAPDH expression (36) .
Western Blotting-For Western blotting, 100-mm dishes of low density neonatal rat cardiac myocytes were incubated in serum-free medium and treated with IL-1␤ or vehicle for 72 h. 50 g of total protein was electrophoresed on a 10% SDS-polyacrylamide gel. Transfer of proteins to nitrocellulose (Scheicher & Schuell) was performed at 4°C for 1 h at 100 mV using a 25 mM Tris, 192 mM glycine, 20% methanol transfer buffer. Following blocking in 5% milk for 1 h, blots were incubated with affinity-purified rabbit polyclonal YY1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) 1:1000 for 2 h at room temperature. After washing, the blots were incubated for 2 h with a 1:1000 dilution of horseradish peroxidase-conjugated secondary antibody, a donkey anti-rabbit IgG (Amersham Corp.). Blots were developed using the ECL detection system (Amersham), subjected to autoradiography, and protein signals quantified by scanning densitometry. Blots were stained with 0.1% Ponceau, 5% acetic acid to correct for differences in loading.
Statistics-Results are presented as mean Ϯ standard error. Treated/control ratios were tested for deviation from unity by calculation of confidence limits and differences between treatments were analyzed by a paired t test using Bonferroni's adjustment for multiple comparisons. A value of p Ͻ 0.05 was considered significant. (Fig. 1 )-Work by a number of laboratories indicate that cardiac myocytes, both in vivo and in vitro, respond to stress with the induction of a characteristic set of genes and gene products. Similar to that seen previously by our co-workers with norepinephrine, cardiac myocytes exposed to the ␣ 1 -adrenergic agonist phenylephrine (20 M) for 48 h showed an increase over control in mRNA expression for both skeletal ␣-actin and ␤-MHC (19, 20) . In contrast, co-treatment with IL-1␤ (1 ng/ml) repressed this ␣ 1 -adrenergic mediated stimulatory effect, while IL-1␤ alone had only a modest inhibitory effect on basal mRNA expression.
RESULTS

IL-1␤ Inhibits ␣ 1 -Adrenergic Induced Skeletal ␣-Actin and ␤-MHC Gene Expression
To determine whether the IL-1␤-mediated inhibition of the ␣ 1 -adrenergic induced gene expression was transcriptional in nature, a transient transfection assay was utilized (26) . In this approach several promoter constructs linked to a CAT reporter gene were transfected into cardiac myocytes (Figs. 1, C and D) .
Transfections with the Ϫ1400 skeletal ␣-actin or the Ϫ3300 ␤-MHC promoter sequences indicated a significant decrease in CAT activity when co-treatment with phenylephrine and IL-1␤ was compared with phenylephrine alone. Under basal conditions, IL-1␤ had a slight down-regulatory (skeletal ␣-actin) or no effect (␤-MHC) relative to control.
To determine whether IL-1␤ acts on the same minimal promoter sequences required for ␣ 1 -adrenergic mediated activation (26, 34) , the Ϫ113 skeletal ␣-actin and Ϫ215 ␤-MHC promoter sequences were transfected into myocytes and exposed to phenylephrine and IL-1␤ for 48 h. Although responsive to phenylephrine treatment, these minimal promoter sequences for both genes were not affected by IL-1␤, indicating that IL-1␤ and phenylephrine do not act through the same promoter sequences.
Consistent with the transcriptional nature of the IL-1␤ effect, skeletal actin mRNA half-life was determined following 24-h exposure to phenylephrine Ϯ IL-1␤ followed by treatment with the transcriptional inhibitor actinomycin D (0.5 g/ml). RNA harvested after various time intervals (2-24 h) was analyzed for actin mRNA and signals compared. Consistent with the findings of others (38) , the t1 ⁄2 for actin is quite long and was unaffected by IL-1 co-treatment (data not shown).
IL-1␤ and Phenylephrine Down-regulate SERCA 2a and ␣-MHC Gene Expression (Fig. 2) -In addition to the characteristic induction of fetal program genes such as skeletal ␣-actin and ␤-MHC, the myocyte expression of several adult, myocytespecific proteins also respond to hypertrophic stimuli both in vivo and in vitro. For example, the myocyte expression of the sarcoplasmic reticulum ATPase and ␣-MHC genes have been reported to be repressed in response to several growth factors (11, 21, 39) . To determine the IL-1␤ effect on the phenylephrine regulation of SERCA 2a and ␣-MHC mRNA, we treated myocytes with IL-1␤, phenylephrine, both, or neither. As shown by Northern analysis, both IL-1␤ and phenylephrine had a negative effect on basal SERCA and ␣-MHC gene expression. In contrast to what found with skeletal ␣-actin and ␤-MHC, however, co-treatment of myocytes with IL-1␤ and phenylephrine did not reverse the ␣ 1 -adrenergic mediated effect, but showed an apparently additive inhibitory effect on both genes. Transfection studies with full-length promoter constructs confirmed the transcriptional nature of the IL-1␤ effects on these genes.
The IL-1␤ Effect Is Not Due to a Generalized Decrease in Transcription (Figs. 3 and 4) -The data indicated above suggest that, despite stimulating an overall increase in myocyte protein content, IL-1␤ treatment results in a decrease in transcriptional activity. To determine whether the decrease in gene expression seen with IL-1␤ was the result of a generalized decrease in polymerase II activity, we examined the effect of IL-1␤ on two immediate early genes (c-myc and c-fos) and the ␤-actin housekeeping gene. As has been seen previously, treatment with the ␣ 1 -agonist phenylephrine resulted in an increase in the steady-state mRNA levels for all three of these genes (40, 41) . 2 Similarly, the mRNAs for both c-myc and c-fos were induced after 2 h of treatment with IL-1␤ (Fig. 3) . Using transfection of c-fos and ␤-actin promoter constructs, we found that IL-1␤ increased c-fos promoter activity and had no demonstrable inhibitory effect on phenylephrine-induced ␤-actin expression (Fig. 4) .
The Bifunctional Transcription Factor YY1 Is Required for IL-1␤-mediated Suppression of Induced Skeletal ␣-Actin Gene Expression (Fig. 5) -Previous reports on the induction of the skeletal ␣-actin gene by transforming growth factor ␤ indicate that the transcription factor YY1 is a negative regulator of skeletal ␣-actin gene expression in cardiac myocytes (31) . Specifically, prevention of YY1 binding to sequences overlapping the proximal serum response element (SRE1) resulted in an increase in both basal and growth factor-stimulated skeletal ␣-actin transcription. To examine whether the negative effect of IL-1␤ on phenylephrine-induced cardiac gene transcription might involve YY1, we transfected the chicken skeletal ␣-actin promoter sequence (Ϫ394 to ϩ24) used by these investigators (with and without the mutated YY1 binding site) into cardiac myocytes, followed by treatment with IL-1␤ and/or phenylephrine as described above. As seen with the full-length (Ϫ1400) mouse construct, the phenylephrine response of the wild type chicken skeletal ␣-actin promoter was inhibited by approximately 75% with IL-1␤ co-treatment. Similar to the findings of MacLellan, when the YY1 binding site of the SRE1 in the chicken skeletal ␣-actin gene (Ϫ81 to Ϫ79) is mutated, both basal and induced promoter activity is higher than in transfections with the wild type promoter construct, consistent with the hypothesis that YY1 is a negative regulator of skeletal ␣-actin gene transcription (42) and confirming the presence of YY1 in cultured neonatal cardiomyocytes under basal conditions (31) . In contrast, the IL-1␤-mediated inhibitory effect on phenylephrine-induced skeletal ␣-actin transcription was lost in the presence of the mutated YY1 binding site. 2 C. S. Long, unpublished observations.
FIG. 2. IL-1␤ and phenylephrine down-regulate SERCA 2a and
␣-MHC gene expression. Low density cultured cardiac myocytes were treated with IL-1␤ (1 ng/ml), phenylephrine (20 M), or their diluent for 48 h and mRNA expression of SERCA (A) and ␣-MHC (B) were analyzed. Autoradiographs were analyzed by densitometry and normalized to GAPDH expression. Similarly, cardiac myocytes were transfected with the full-length promoter-CAT-construct of SERCA (C). All dishes were co-transfected with SV40-SEAP (0.2 g) to control for transfection efficiency. CAT activities were calculated relative to the SEAP activity in the same dish. Control values were set at 1. Results shown are from n ϭ 3-5 different experiments. CAT assays were performed in duplicate for each condition. CON, control; PHY, phenylephrine.
Species-related Differences of the SRE1 Sequence in the Skeletal ␣-Actin Promoter Explain the Loss of the IL-1␤ Effect on
Ϫ113 Skeletal ␣-Actin-CAT-Since the mouse Ϫ113 skeletal ␣-actin promoter also contains a proximal SRE1, it was unclear why there was no IL-1␤-mediated inhibitory effect seen with this construct (Fig. 1C) . In an effort to explain the differences seen between the chicken and mouse skeletal ␣-actin constructs, the sequences adjacent to the proximal SRE's of the two promoter elements were compared. As shown in Fig. 5B , alignment with the mouse skeletal ␣-actin promoter showed that the SRE1 in the Ϫ113 skeletal ␣-actin promoter does not contain the YY1 consensus sequence, with a T for G substitution at a position critical for YY1 binding (31) .
To determine whether this single base pair difference in SRE1 between the mouse and the chicken skeletal ␣-actin promoter was responsible for the IL-1␤-mediated effect, we examined the effect of creating an "artificial" YY1 binding site in the mouse Ϫ113 skeletal ␣-actin promoter element (GC for TT substitution). As indicated in Fig. 6 , transfections with the Ϫ113 skActin-Mutant-CAT construct restored the IL-1␤-mediated repression of phenylephrine induction confirming that an intact YY1 binding site is both necessary and sufficient for the IL-1␤ effect in the skeletal ␣-actin promoter.
A (Fig. 6 )-Using several deletion mutant constructs linked to the CAT reporter plasmid, we further characterized the IL-1␤ response element in the mouse skeletal ␣-actin promoter. As shown in Fig. 6 , the 127-bp element from Ϫ240 to Ϫ113 is required for the IL-1␤-mediated repression of ␣ 1 -induced skeletal ␣-actin transcription. Further support for the role of YY1 as a mediator of IL-1␤ repression was provided using the co-transfection of a YY1 expression vector with the various mouse skeletal ␣-actin promoter constructs. As noted, co-transfected YY1 repressed ␣ 1 -adrenergic induced skeletal ␣-actin promoter activity and co-localized with the IL-1␤ response element (Fig. 6) . Consistent with the trend for the IL-1␤ suppression of skeletal ␣-actin under control conditions, overexpression of YY1 alone (without phenylephrine treatment) slightly but not significantly repressed basal expression of both Ϫ1400 and Ϫ240 skeletal ␣-actin promoter constructs (data not shown). Furthermore, as shown previously (Fig. 5) , co-transfected YY1 had no effect on the wild-type mouse Ϫ113 promoter construct but repressed ␣ 1 induction of the mutated mouse Ϫ113 skeletal ␣-actin promoter construct. Evaluation of the Cardiac myocytes were transfected with promoter-CAT constructs of c-fos (A) and ␤-actin (B) as described. Cells were then treated with IL-1␤ (1 ng/ml), phenylephrine (20 M), or diluent for 48 h (24 h for c-fos). All dishes were co-transfected with SV40-SEAP (0.2 g) to control for transfection efficiency. CAT activities were calculated relative to the SEAP activity in the same dish. The lower figures illustrate representative autoradiographs showing the differences in CAT activity under basal and stimulated conditions. The relative CAT activity of the control samples was set at 1. Results shown are from n ϭ 3-5 different experiments (performed in duplicate) for each condition. CON, control; PHY, phenylephrine. sequence in the 127-bp fragment indicate the presence of two other "upstream" SREs in the skeletal ␣-actin promoter. Although not required for ␣ 1 -stimulated skeletal ␣-actin promoter activity (26) , one of the upstream SREs (SRE3) does contain the YY1 consensus sequence.
127-bp Element Is Required for IL-1␤-mediated Repression of the Mouse Skeletal ␣-Actin Promoter and Co-localizes with YY1-mediated Repression
IL-1␤ Increases YY1 Protein Expression (Fig. 7) -To determine whether IL-1␤ induces the abundance of YY1 protein in cardiac myocytes as a potential explanation for the IL-1␤ effect, cells were treated with cytokine for 72 h and YY1 protein quantified by Western blotting. As indicated in Fig. 7 , consistent with the findings of MacLellan et al. (31) , control neonatal cardiac myocytes contain constitutively expressed YY1 protein that is further increased nearly 2-fold by IL-1␤ treatment.
DISCUSSION
The main finding of the present study is that IL-1␤ is a negative transcriptional regulator of myocyte-specific gene expression in cultured neonatal cardiac myocytes. This observation extends our previous report on the unique phenotype of myocyte hypertrophy induced by IL-1␤ and serves to separate this agent further from other hypertrophic agents. Furthermore, the increases in skeletal ␣-actin and ␤-MHC mRNA accumulation following ␣ 1 stimulation are markedly reduced in the presence of IL-1␤, indicating that this cytokine can actively repress the induction of these muscle-specific genes. IL-1␤ also reduced basal levels of both SERCA 2a and ␣-MHC gene expression similar to that seen with ␣ 1 stimulation, and both agents together were able to enhance the inhibitory effect of each of the agents alone. Using a transient transfection assay to identify the promoter elements required for ␣ 1 induction of both the skeletal ␣-actin and ␤-MHC genes, we have confirmed that IL-1␤ acts at the transcriptional level and that the elements responsible for the IL-1␤ effect do not overlap with those required for ␣ 1 induction. Further support for the transcriptional nature of the IL-1␤ effect is provided by the finding that IL-1␤ does not accelerate skeletal actin mRNA degradation.
Although there was a trend for the inhibition of the basal transcription of both skeletal ␣-actin and ␤-MHC genes in the presence of IL-1␤, this only reached statistical significance when they were induced by ␣ 1 stimulation. Since SERCA 2a is normally more abundant in cardiac myocytes, basal transcriptional levels were higher with the SERCA 2a promoter construct than with either skeletal ␣-actin or ␤-MHC, allowing for a more clear inhibition of basal SERCA expression. This observation suggests that a basal inhibitory effect of IL-1␤ on ␤-MHC and skeletal ␣-actin expression probably does exist, but is more visible in the induced state because of the low levels of gene expression in control cells.
Two findings from this study further support the hypothesis that IL-1␤ does not induce a generalized decrease in myocyte (45), the SRE1 of the mouse skeletal ␣-actin promoter (26) , and the YY1 consensus sequence (42) . The mouse SRE1 does not contain a YY1 binding site, whereas the chicken SRE1 is identical with the YY1 consensus sequence. gene expression, but rather the repression of muscle-specific gene products. First, both of the immediate early genes c-fos and c-myc are activated by IL-1␤, an observation which is similar to that seen with ␣ 1 -adrenergic stimulation. This effect is also transcriptionally mediated as shown by the induction of the c-fos promoter in IL-1␤-treated cells. Second, the induction of the housekeeping ␤-actin promoter by ␣ 1 stimulation was unaffected by IL-1␤ co-treatment. In addition, previous experiments indicate that IL-1␤ increases mRNA and protein expression of both the Ca 2ϩ -independent NO Synthase (43, 44) 3 and the intercellular adhesion molecule (ICAM-1) 4 in cardiac myocytes after 48-h treatment.
In view of the previous report on the negative effect of the transcription factor YY1 on skeletal ␣-actin gene expression, it was critical to determine the potential role of this factor in the IL-1␤-mediated effects we observed. Our studies indicate that the IL-1␤-mediated negative transcriptional regulation of the skeletal ␣-actin gene requires an intact YY1 binding site and further suggest that repression of ␣ 1 -induced skeletal ␣-actin gene expression by IL-1␤ might involve, at least in part, action of this transcription factor. The YY1 binding site in the chicken skeletal ␣-actin promoter used in this study is a part of the proximal serum response element (SRE1) and overlaps the serum response factor binding site (31, 45, 46) . As such, alterations in the relative amounts of these two factors may determine the overall activity of the actin promoter (42, 47) . Comparison with the mouse Ϫ113 skeletal ␣-actin promoter used in previous transfection studies (known to include the SRE1 (26) indicate that the SRE1 of the mouse promoter differs from the chicken SRE1 at a critical nucleotide for YY1 binding. This observation likely explains why the inhibitory effect of IL-1␤ was lost in transient transfection studies using the Ϫ113 promoter of the mouse skeletal ␣-actin gene and indicate that the IL-1␤-responsive area is upstream of the ␣ 1 -responsive elements. In addition, a mutation of the SRE1 in the mouse minimal promoter, regenerating a YY1 binding site, re-established IL-1␤-mediated inhibition of ␣ 1 -adrenergic induction creating, in fact, a "YY1-responsive" promoter element. These results indicate that the differences in the SRE1 sequences between the two species explain the differences seen with IL-1␤ treatment of the chicken and minimal mouse skeletal ␣-actin promoter and underlines the importance of the transcription factor YY1 in mediating the IL-1␤ effect.
Mapping of the mouse skeletal ␣-actin promoter indicates that the region from Ϫ240 to Ϫ113 is required for the inhibitory effect of IL-1␤. Co-transfection of a YY1 expression vector showed repression to the same extent as IL-1␤ in phenylephrine-treated cells and co-localized with the IL-1␤ response, indicating that YY1 may bind to a site in the Ϫ240 to Ϫ113 element of the mouse skeletal ␣-actin promoter. As noted previously, this 127-bp promoter fragment contains two additional SREs (SRE2 and SRE3), one of which includes the YY1 consensus sequence. Similarly, the rat ␤-MHC promoter contains two YY1 consensus sequences at the positions Ϫ1080 bp and Ϫ1262 bp, consistent with our finding that the IL-1␤ effect is detectable in transfection studies with the maximal promoter sequence (Ϫ3300), but not with the minimal promoter (Ϫ215). Supporting the importance of YY1 in IL-1␤-mediated gene regulation, we found that the c-fos promoter is activated by cotransfected YY1 (data not shown). Since IL-1␤ also activates the c-fos promoter, it could be speculated that induction of the c-fos promoter by IL-1␤ might also be mediated by YY1 as suggested by others (48) . In addition, IL-1␤ increased YY1 protein content, indicating a direct link between IL-1␤ and gene transcription. In contrast, although we were able to show an inhibitory effect of IL-1␤ on the regulation of SERCA 2a and ␣-MHC genes, there are no known YY1 consensus sequences in their promoters, indicating that other transcription factors are also involved in the IL-1␤ regulation of myocardial gene expression.
The induction of a hypertrophic state by IL-1␤, which is characterized by the down-regulation of specific contractile protein isogene expression in culture, might provide a mechanism for the progressive loss of contractile function seen with several pathophysiologic states in vivo. For example several forms of reactive myocardial hypertrophy in vivo are accompanied by enhanced systemic catecholamine levels (49) , and the observation of others that cytokines, such as IL-1␤, blunt catecholamine-induced contractility (12) (13) (14) 16) indicate that cytokines may be important modulators of contractile function during hypertrophy. It is also interesting to speculate that cytokines, such as IL-1␤, may be responsible, at least in part, for the decreased contractility seen during myocardial injury as an adaptation to a decrease in substrate supply during ischemia. Furthermore, the negative inotropic effect seen during stunning could be related to the negative effect of cytokines on contractile gene expression, an observation that may help to explain the delay in contractile recovery following coronary reperfusion.
In summary, this study demonstrates for the first time that IL-1␤ is a negative transcriptional regulator of muscle-specific genes in cultured neonatal rat cardiac myocytes. There is further evidence that the bifunctional transcription factor YY1 is one of the mediators of the IL-1␤ effect. Taken with our previous findings that IL-1␤ can re-initiate myocyte DNA synthesis, these findings emphasize the unique phenotype induced by IL-1␤ and suggest that this cytokine may act in a general way to withdraw the cardiac myocyte from the differentiated phenotype. Further work to address this hypothesis will focus on two areas of investigation: 1) identifying the factors in addition to YY1 that are responsible for the decrease in myocyte-specific gene expression and 2) exploring the interaction of these factors with the induction of cell-cycle related genes and gene products in response to IL-1␤. In this regard, it is noteworthy that factors such as the retinoblastoma gene product (Rb) have been reported to function both as transcriptional repressors and inducers of cellular proliferation (50 -52) .
